Literature DB >> 8218952

A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients.

T Sekine1, H Shiraiwa, T Yamazaki, K Tobisu, T Kakizoe.   

Abstract

Cultivation of T lymphocytes with immobilized anti-CD3 monoclonal antibody and human recombinant interleukin-2 induced a rapid proliferative response. This procedure was applied to expansion culture of peripheral blood lymphocytes obtained from cancer patients for use in adoptive immunotherapy. Peripheral blood mononuclear cells were separated from 20 ml of blood and cultured in anti-CD3 coated flasks with rIL-2 for 6 days, then transferred to a gas-permeable culture bag and culture continued for an additional 8 days with an increasing volume of medium. Cell numbers increased about 2000-fold during this 2-week culture. The final population contained about 30% CD4+ and 60% CD8+ cells, and all were CD3+ & HLA-DR+. NK cells comprised less than 5%. In clinical trials involving 12 cases receiving 35 infusions, the mean number of harvested T cells after 14 days culture was 3.5 x 10(10) (R = 1.6-6.8 x 10(10)), and the mean expansion index was 1560-fold (R = 409-4091). This method could be of benefit not only in immunotherapy but also for obtaining somatic cells from a small volume of blood for use in molecular or genetic analysis instead of having to perform EB virus transformation of B cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8218952     DOI: 10.1016/0753-3322(93)90294-u

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay.

Authors:  Hideki Harada; Kaoru Saijo; Isamu Ishiwata; Tadao Ohno
Journal:  Hum Cell       Date:  2004-03       Impact factor: 4.174

2.  Prolonged overall survival in gastric cancer patients after adoptive immunotherapy.

Authors:  Guo-Qing Zhang; Hong Zhao; Jian-Yu Wu; Jin-Yu Li; Xiang Yan; Gang Wang; Liang-Liang Wu; Xiao-Gang Zhang; Yi Shao; Yu Wang; Shun-Chang Jiao
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

3.  Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.

Authors:  Bao-Gang Peng; Li-Jian Liang; Qiang He; Jie-Fu Huang; Ming-De Lu
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

4.  Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale.

Authors:  H Bohnenkamp; U Hilbert; T Noll
Journal:  Cytotechnology       Date:  2002-01       Impact factor: 2.058

5.  Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report.

Authors:  Yanyan Long; Qiong Sun; Jianyu Wu; Yu Wang; Shunchang Jiao
Journal:  Oncol Lett       Date:  2014-02-24       Impact factor: 2.967

6.  Influence of transfusion of lymphokine-activated T killer cells on inflammatory responses in dogs after laparotomy.

Authors:  Keiichiro Mie; Mizuki Tomihari; Kiyotaka Hoshi; Takashi Nakamura; Tomohiro Yamaguchi; Kazuro Miyahara; Terumasa Shimada
Journal:  J Vet Med Sci       Date:  2016-01-02       Impact factor: 1.267

7.  Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia.

Authors:  Luiza Cunha Junqueira Reis; Virgínia Picanço-Castro; Bárbara Cristina Martins Fernandes Paes; Olívia Ambrozini Pereira; Isabela Gerdes Gyuricza; Fabiano Tófoli de Araújo; Mariana Morato-Marques; Lílian Figueiredo Moreira; Everton de Brito Oliveira Costa; Tálita Pollyanna Moreira Dos Santos; Dimas Tadeu Covas; Lygia da Veiga Pereira Carramaschi; Elisa Maria de Sousa Russo
Journal:  Stem Cells Int       Date:  2017-07-26       Impact factor: 5.443

8.  Cytotoxic activity of CD4+ T cells against autologous tumor cells.

Authors:  Y Konomi; T Sekine; T Takayama; M Fuji; T Tanaka
Journal:  Jpn J Cancer Res       Date:  1995-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.